Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 333 LAKESIDE DR FOSTER CITY CA 94404 |
Tel: | N/A |
Website: | https://www.gilead.com |
IR: | See website |
Key People | ||
Daniel P O'Day Chairman of the Board, Chief Executive Officer | Andrew D. Dickinson Chief Financial Officer | Deborah H. Telman Executive Vice President - Corporate Affairs, General Counsel |
Johanna Mercier Chief Commercial Officer | Merdad V. Parsey Chief Medical Officer |
Business Overview |
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries. |
Financial Overview |
For the three months ended 31 March 2024, Gilead Sciences, Inc. revenues increased 5% to $6.69B. Net loss applicable to common stockholders totaled $4.17B vs. income of $1.01B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Acquired in-process research and develop increase from $481M to $4.13B (expense). |
Employees: | 18,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $27,450M as of Mar 31, 2024 |
EBITDA (TTM): | $11,631M as of Mar 31, 2024 |
Net annual income (TTM): | $484.00M as of Mar 31, 2024 |
Free cash flow (TTM): | $5,166M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 1,246,000,000 as of Mar 31, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |